Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Boston Scientific ( (BSX) ) has shared an update.
On March 28, 2026, Boston Scientific announced positive results from the HI-PEITHO global randomized clinical trial showing that its EKOS Endovascular System, when used with anticoagulation, was superior to anticoagulation alone in treating patients with intermediate-risk acute pulmonary embolism. The data, presented at ACC.26 and published in The New England Journal of Medicine, demonstrated a statistically significant 61% reduction in the composite primary endpoint of PE-related mortality, non-fatal hemodynamic cardiorespiratory decompensation or collapse, and non-fatal symptomatic PE recurrence within seven days, without increased major bleeding and with shorter hospital stays.
The HI-PEITHO trial enrolled 544 patients across 59 sites in the U.S. and Europe and found notably lower rates of cardiorespiratory decompensation or collapse in the EKOS-treated group, with no intracranial bleeding events through 30 days. These robust randomized data strengthen the clinical case for ultrasound-facilitated, catheter-directed thrombolysis as a potential first-line therapy in intermediate-risk PE, enhancing Boston Scientific’s position in the vascular therapies market and providing interventionalists and referring physicians with evidence to support broader adoption of the EKOS system in clinical practice.
The most recent analyst rating on (BSX) stock is a Buy with a $105.00 price target. To see the full list of analyst forecasts on Boston Scientific stock, see the BSX Stock Forecast page.
Spark’s Take on BSX Stock
According to Spark, TipRanks’ AI Analyst, BSX is a Neutral.
The score is primarily supported by strong underlying financial performance and an upbeat earnings outlook (double-digit growth, EPS and margin expansion, and higher expected free cash flow). These positives are tempered by weak technicals (clear downtrend despite oversold readings) and a premium valuation (high P/E), with corporate actions supportive but adding some leverage/execution risk around acquisitions.
To see Spark’s full report on BSX stock, click here.
More about Boston Scientific
Boston Scientific Corporation is a global medical technology company that develops and manufactures devices and therapies used to diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases. With more than 45 years in the industry, the company focuses on high-performance solutions that aim to address unmet patient needs and reduce the overall cost of healthcare worldwide.
Average Trading Volume: 15,094,477
Technical Sentiment Signal: Hold
Current Market Cap: $102.6B
For an in-depth examination of BSX stock, go to TipRanks’ Overview page.